A complex $26 billion global deal reaches a critical juncture on Friday: Drug companies must decide whether to walk away from an agreement to provide funds to nearly all 50 states and U.S. territories to abate costs caused by the opioid crisis. A key factor in that decision is how many of the thousands of cities and counties within each state chose to participate.

In the weeks leading up to the upcoming deadline, a handful of states, such as New Jersey and Connecticut, announced that 100% of their municipalities were on board with the deal, which involves a $5 billion agreement with manufacturer Johnson & Johnson’s Janssen Pharmaceuticals, and a $21 billion settlement with three drug distributors: AmerisourceBergen Drug Corp., McKesson Corp. and Cardinal Health Inc. Many, such as California and Florida, were close to that goal.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]